NOVARTIS N (NOVN.VX)
-VTX 73.65 
1.25(1.73%) 11:31AM EDT
| Prev Close: | 72.40 |
|---|
| Open: | 72.30 |
|---|
| Bid: | 73.65 |
|---|
| Ask: | 73.70 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 72.20 - 73.75 |
|---|
| 52wk Range: | N/A |
|---|
| Volume: | 4,954,414 |
|---|
| Avg Vol (3m): | N/A |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CHF.
Headlines
- New Flu Vaccine Beats Current Products in Animal Testingat Bloomberg(Wed 1:00PM EDT)
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campusat Bloomberg(Wed 10:39AM EDT)
- European Stock-Index Futures Little Changed Before Summitat Bloomberg(Wed 2:16AM EDT)
- Novartis Ramping Up Alzheimer’s Pursuit as Rivals’ Drugs Failat Bloomberg(Tue, May 21)
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Excitingat Bloomberg(Tue, May 21)
- Swiss stocks - Factors to watch on May 21at Reuters(Tue, May 21)
- [video] Taking Meds Goes High-Techat MarketWatch(Mon, May 20)
- Indonesia's nationwide healthcare plan stumbles at first hurdleat Reuters(Sun, May 19)
- ThromboGenics Reports Jetrea Sales as Drug Fails Mid-Stage Studyat Bloomberg(Thu, May 16)
- DEALTALK-Novartis' Vasella exit opens door to Roche stake saleat Reuters(Thu, May 16)
- Novartis says has no intention of buying Actavisat Reuters(Thu, May 16)
- [$$] Drug Firms Stalk Actavisat The Wall Street Journal(Wed, May 15)
- SEC says new settlements end 'Golden Goose' insider trading caseat Reuters(Wed, May 15)
- New cancer tools allow patients to reconsider chemoat Reuters(Wed, May 15)
- South Korea's Celltrion sale seen slow-going as sceptics emergeat Reuters(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forNOVN.VX.